$2.44? Did I read a different analysis of the CHF results that...

$2.44?

Did I read a different analysis of the CHF results that did not include:

60% reduction in incidence of ischemic MACE (heart attack or stroke) across entire 537 patient study population, irrespective of NYHA class II or III, ischemic or non-ischemic etiology(p=0.002)
30% reduction in incidence of three-point MACE (cardiac death, heart attack or stroke) across entire 537 patient study population (p=0.027)
55% reduction in incidence of three-point MACE (cardiac death, heart attack or stroke) in NYHA class II patients (n=206) (p=0.009)
60% reduction in cardiac death in NYHA class II patients (p=0.037) and prevention of progression to NYHA class III rate of cardiac death

A 60% reduction in Class II patients progression to Class III? That is massive.

Novartis' Entresto consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan, used instead of an ACE inhibitor or an angiotensin receptor blocker. MSB even put those on its nice diagrams to show where someone like Novartis or Sanofi might see a huge potential for MSB's treatment in complementing stage 1 and early stage II treatments using their existing products.

I know if I had chronic heart failure I'd be asking for both....